Home | Site map | Elsevier websites | Alerts
Elsevier
Product information search
Search all Elsevier sites
Search
Advanced Product Search
Go to Elsevier home page
SiteStat.jsp
NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY AND MEDICINE
Official Publication of the American Academy of Nanomedicine

Guide for Authors



Editor-in-Chief
Chiming Wei, MD, PhD, FACC, FAHA
Ellicott City, MD

Co-Editor-in-Chief
Tachung C. Yih, PhD, PE
Rochester, MI

EDITORIAL OFFICE:

For submission and correspondence related Abstracts, Posters, Conference Summaries, and Book Reviews:
Nanomedicine
c/o Chiming Wei, MD, PhD
Phone: 443-326-8548
Email: nanomedicine@gmail.com

For all other submissions:
Managing Editor
Alice Landwehr
Tucson, Arizona
nanomedicine@cox.net

PUBLISHER
Elsevier Inc.
360 Park Avenue South
New York, NY 10010-1710

Aims and Scope of the Journal

Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine) is an international, peer-reviewed journal. Each quarterly issue of Nanomedicine presents basic, clinical, and engineering research in the field of nanomedicine. Article categories include basic, diagnostic, experimental, clinical, engineering, pharmacologic, and toxicologic nanomedicine. In addition, regular features will address the commercialization of nanomedicine advances, ethics in nanomedicine, funding opportunities, and other topics of interest to researchers and clinicians. We invite authors to submit original manuscripts and review articles.

General Policies and Instructions for Authors

Peer Review

All manuscripts will be evaluated for completeness and adherence to submission guidelines and will then undergo a peer-review process. Provisional or final acceptance is based on originality, scientific accuracy, relevance, clarity, and topical balance of the Journal. Authors should suggest the names (with contact information) of three potential reviewers for the manuscript. Every attempt will be made to use at least one suggested reviewer. A request to submit a revised manuscript does not guarantee its acceptance, only that it will be reconsidered by the reviewers. Decisions will be communicated to the corresponding author by e-mail.

Conflict of Interest

Authors are required to acknowledge all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. Each submission must also include a publishable statement on the title page disclosing any commercial associations, current and within the past five years, that might pose a potential, perceived, or real conflict of interest. These include grants, patent licensing arrangements, consultancies, stock or other equity ownership, advisory board memberships, or payments for conducting or publicizing the study.

When no competing interests are present, include a statement on the title page. The editor asks each reviewer to disclose any competing interests or to recuse oneself if a competing interest might interfere with one's objectivity.

National Institutes of Health Public Access Policy

Certain repositories such as PubMed Central (PMC) are authorized under special arrangement with Elsevier to process and post certain articles such as those funded by the National Institutes of Health under its Public Access policy (see elsevier.com for more detail on our policy). Articles accepted for publication in an Elsevier journal from authors who have indicated that the underlying research reported in their articles was supported by an NIH grant will be sent by Elsevier to PMC for public access posting 12 months after final publication. The version of the article provided by Elsevier will include peer-review comments incorporated by the author into the article. Because the NIH Public Access policy is voluntary, authors may elect not to deposit such articles in PMC. If you wish to 'opt out' and not deposit to PMC, you may indicate this by sending an e-mail to: NIHauthorrequest@elsevier.com.

Requirements for studies involving live human or animal subjects:

For studies that involved human or animal research, indicate approval by the institution's human or animal subject review committee in the Methods section of the manuscript. Include an additional statement of the humane care of the animals with animal studies and a statement of informed consent or exempt classification by the IRB with human studies.

Submission of Manuscripts

Manuscripts must be submitted through the Nanomedicine online submission and review Web site (External link http://ees.elsevier.com/nano ). All manuscripts submitted to the Journal must be original and must not have been previously published elsewhere or currently under consideration by another publication. In an accompanying letter, authors should state that the manuscript, or part of it, have not been and will not be submitted elsewhere for publication. In an accompanying letter, authors should state that the manuscript, or any part of it, is not and will not be submitted elsewhere for publication while under consideration by Nanomedicine.

Manuscript Preparation

Submission items include a cover letter, a list of suggested reviewers, the manuscript (including title page, abstract, manuscript text, references, and table/figure legends), tables, and figures. Revised manuscripts should also be accompanied by a unique file (separate from the covering letter) with responses to reviewers' comments.

The preferred order of files is as follows: cover letter, suggested reviewers, response to reviews (revised manuscripts only), manuscript file(s), table(s), figure(s). Files should be labeled with appropriate and descriptive file names (e.g., SmithText.doc, Fig1.eps, Table3.doc). Upload text, tables and graphics as separate files. Do not import figures or tables into the text document and do not upload your text as a PDF.

Full-length article manuscripts should not exceed 6000 words in total length (including title page, abstract, text, references, tables, and figure legends), or contain more than 10 tables and figures. Manuscripts must be typed, double-spaced and assembled in this order: title page, abstract, text, acknowledgments, references, figure legends, tables and figures. Leave 1-inch margins on all sides. All manuscripts must conform to "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (External link http://www.icmje.org ).

PERMISSIONS: If any material has been published previously (figure, tables, etc), provide written permission from the copyright holder to use such material. Authors are responsible for obtaining permission and payment of any fees associated with reuse.

TITLE PAGE: The title page should contain these elements: full title, all authors' names, academic degrees, and affiliations; short title (not to exceed 50 characters, including spaces); name and complete address for corresponding author and address for reprints if different from correspondence; fax and telephone number and e-mail address; conflict of interest statement if applicable; all sources of support for research.

ABSTRACT: The abstract should not exceed 150 words and should summarize the content of the aricle. Insert 3 to 5 key words after the abstract.

TEXT: For Original Articles, the text should include the headings Background, Methods, Results, and Discussion. All pages must be numbered. Abbreviations must be parenthetically notated at first mention in the text. Each table and figure must be mentioned in the text. Reports of studies on humans and animals must indicate that each study was approved by an institutional review committee and the procedures followed were in accordance with institutional guidelines. Provide generic rather than trademarked names of drugs.

ACKNOWLEDGMENTS: The acknowledgments section recognizes substantive contributions of individuals. The Editorial Office must receive written, signed consent from each person recognized in the acknowledgments to be mentioned in the article because acknowledgment can imply endorsement of data and conclusions; upload each permission separately in the online system. Do not include statements of funding, conflicts, or other disclosures in the Acknowledgments; these must appear on the title page.

REFERENCES: Reference format should conform to that set forth in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (External link http://www.icmje.org ) and journal abbreviations should conform to the style used in the Cumulated Index Medicus. Cite references, figures, and tables in numeric order according to the first mention in the text. Accuracy of reference data is the responsibility of the author. Verify all references against original sources. "In press" citations must have been accepted for publication and the name of the journal or book publisher must be included. The style of citation should be as follows:

Journals: authors' last names and initials; title of article; journal name; date; volume number, and inclusive pages (list all authors when six or fewer; when seven or more, list six and add et al):
1. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999;117:719-27.
2. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, et al. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 1999;117:855-72.

Books: authors' last names and initials; chapter title, editor's name, book title, edition, city, publisher, date, and pages:
1. Mollnes TE. Analysis of in vivo complement activation: In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, editors. Weir's handbook of experimental immunology. Volume 78, 5th ed. Boston: Blackwell Science; 1997, p. 1-8.

Unpublished data and personal communications should be cited only in the text, not as a numbered reference. Authors wishing to cite unpublished material must have a letter of permission from the originator of the communication to do so. This letter should be submitted with the manuscript.

FIGURES: Figures must be of professional quality. When possible, please use first-generation artwork. Figures are encouraged in electronic format. Figures may be black and white line art, graphs, halftones (photographs), or color. Be sure that figures are submitted in .tif or .eps format. Line art (black lines on a white background) must have a minimum resolution of 1,000 dpi. Combination line art (eg, line art with gray fill patterns) must be created at 500 dpi. Black and white or color photographs must have a minimum resolution of 300 dpi.

Produce images near to the desired size of the printed version. Illustrations should be saved at the recommended resolution setting and sized as close to a column width (3 to 4 inches) as possible. Create figures in scale with each other to the extent possible. Avoid background gridlines and other formatting that do not convey information (eg, superfluous use of 3-dimensional formatting, background shadings). Use uniform lettering and sizing of all original artwork. As a general rule the lettering on the artwork should have a finished, printed size of 7 points. Smaller lettering will yield barely legible text. Recommended font choices include Arial, Helvetica, or Symbol. Labeling of multipart figures (eg, A, B, C...) should use capital letters only and should be done consistently, preferably using uppercase type (Arial, Helvetica or Universe, 11 or 12 points) in the lower-right corner of the figure. Avoid headings on the figure when possible. Additional information on preparation of electronic artwork can be found in the Artwork Instructions available at External link http://authors.elsevier.com/ . For best results, please follow these guidelines carefully. Publication of color illustrations in the print Journal will be charged to the author.

TABLES: Table numbers should be Arabic, followed by a period and a brief title. Begin each table on a separate page. Use same size type as in text where possible. Supply a brief heading for each column. Do not use vertical lines between columns. Use horizontal lines above and below the column headings and at the bottom of the table only. Use extra space to delineate sections within the table. Abbreviations used in the table must be defined in a footnote to the table. Indicate footnotes in this order: symbols.

VIDEOS: Nanomedicine is pleased to offer hosting of videos! Authors are encouraged to submit videos that give readers a fuller understanding of the article. Supplementary movies or animation files that supplement a submitted article should be provided in one of the following preferred formats: .mpg, .mov, .avi, or .gif. All videos are subject to peer review. For more details, please visit External link http://www.elsevier.com/wps/find/authorsview.authors/movies_animations.

Content Types:

  1. BASIC NANOMEDICINE INVESTIGATIONS: Studies using nanotechnology to answer basic medical and biologic questions such as cell activity, DNA and RNA regulation, intracellular pathways, and nanosurgery.
  2. DIAGNOSTIC NANOMEDICINE INVESTIGATIONS: Studies using nanotechnology for diagnostic research and imaging development.
  3. EXPERIMENTAL NANOMEDICINE INVESTIGATIONS: Studies in laboratory animal experiments and in vitro experiments related to nanomedicine.
  4. CLINICAL NANOMEDICINE INVESTIGATIONS: Studies in clinical nanomedical science such as the approach of nanomedicine to prevent or treat different diseases.
  5. ENGINEERING NANOMEDICINE INVESTIGATIONS: Studies in development of engineering nanomedical technology in a medical specialty.
  6. PHARMACOLOGICAL NANOMEDICINE: Studies in drug delivery, pharmacologic mechanisms and particles.
  7. TOXICOLOGY NANOMEDICINE: Studies in side effects and toxicology.
  8. COMMERCIALIZATION OF NANOMEDICINE: Information regarding the commercialization of new products in the field.
  9. ETHICS IN NANOMEDICINE: Articles related to the ethical application of advances in nanomedicine.
  10. EDITORIAL COMMENTS: Invited articles or brief editorial comments that represent opinions of recognized leaders in nanomedicine research; length should not exceed 3000 words, and no more than 20 references should be cited.
  11. SCIENTIFIC REVIEWS: Review articles of selected important topics in nanomedicine research. Length should not exceed 10,000 words (including title page, abstracts, text, references, tables, and figure legends), and the article should have no more than 15 figures. No more than 150 references should be cited, which may be posted online only.
  12. BOOK REVIEWS: Reviews of selected books in nanomedicine, including books that present innovative concepts and books that describe state-of-the-art diagnostic or therapeutic methods or important advances; Authors should submit books for review to the Nanomedicine Editorial Office.
  13. TECHNICAL NOTES: Length of technical notes should not exceed 1,200 words, 4 figures, and 10 references.
  14. CORRESPONDENCE: Letters to the Editor may not exceed 500 words with 10 references or fewer and one illustration or table.
  15. MEETING INFORMATION: Meeting information regarding upcoming nanomedicine conferences. Please contact Elsevier advertising department for rates (212-989-5800).


OFFPRINTS: Offprint order forms will be sent to authors before articles are published. Reprints in quantity must be purchased from the Publisher.



Updated June 2008
For Authors
Submit your article
Artwork instructions
Track your accepted article
Printer-friendly version   Printer-friendly version
 Home | Site map | Privacy policy | Terms and Conditions | Feedback | A Reed Elsevier company
 Copyright © 2008 Elsevier B.V. All rights reserved.